Two Sigma Advisers
NMRA icon

Two Sigma Advisers’s Neumora Therapeutics NMRA Stock Holding History

Two Sigma Advisers’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,083,400
Closed -$1.94M – 1410
2025
Q4 		$1.94M Buy
1,083,400
+106,400
+11% +$233K ﹤0.01% 1204
2025
Q3 		$1.78M Sell
977,000
-252,100
-21% -$407K ﹤0.01% 1190
2025
Q2 		$901K Buy
1,229,100
+1,052,900
+598% +$798K ﹤0.01% 1495
2025
Q1 		$176K Buy
+176,200
New +$302K ﹤0.01% 2167
2024
Q3 		– Sell
-30,800
Closed -$303K – 2443
2024
Q2 		$303K Buy
+30,800
New +$319K ﹤0.01% 2060

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Two Sigma Advisers's NMRA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 1,083,400 shares — an estimated $1.94M sold.

Two Sigma Advisers first reported a position in NMRA in Q2 2024 and held it in 5 quarters. The position peaked at $1.94M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,083,400 Neumora Therapeutics shares in Q1 2026, an estimated $1.94M.
  • Two Sigma Advisers first reported a position in Neumora Therapeutics in Q2 2024 and held it in 5 quarters.
  • Two Sigma Advisers's Neumora Therapeutics position peaked at $1.94M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.